105 related articles for article (PubMed ID: 6353233)
1. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU).
Boice JD; Greene MH; Killen JY; Ellenberg SS; Keehn RJ; McFadden E; Chen TT; Fraumeni JF
N Engl J Med; 1983 Nov; 309(18):1079-84. PubMed ID: 6353233
[TBL] [Abstract][Full Text] [Related]
2. Acute leukemia after adjuvant therapy of gastrointestinal cancer with semustine (methyl-CCNU).
N Engl J Med; 1984 Apr; 310(16):1057-8. PubMed ID: 6708984
[No Abstract] [Full Text] [Related]
3. Leukemia after adjuvant chemotherapy with semustine (methyl-CCNU)--evidence of a dose-response effect.
Boice JD; Greene MH; Killen JY; Ellenberg SS; Fraumeni JF; Keehn RJ; McFadden E; Chen TT; Stablein D
N Engl J Med; 1986 Jan; 314(2):119-20. PubMed ID: 3941685
[No Abstract] [Full Text] [Related]
4. Leukemia following chemotherapy for breast cancer.
Curtis RE; Boice JD; Moloney WC; Ries LG; Flannery JT
Cancer Res; 1990 May; 50(9):2741-6. PubMed ID: 2328500
[TBL] [Abstract][Full Text] [Related]
5. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.
Pedersen-Bjergaard J; Larsen SO
N Engl J Med; 1982 Oct; 307(16):965-71. PubMed ID: 7110299
[TBL] [Abstract][Full Text] [Related]
6. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
7. Leukemia after therapy with methyl CCNU.
Cohen RJ
N Engl J Med; 1980 Jan; 302(2):120. PubMed ID: 6927914
[No Abstract] [Full Text] [Related]
8. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials.
Greene MH; Boice JD; Greer BE; Blessing JA; Dembo AJ
N Engl J Med; 1982 Dec; 307(23):1416-21. PubMed ID: 6752720
[TBL] [Abstract][Full Text] [Related]
9. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
[TBL] [Abstract][Full Text] [Related]
10. Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.
Douglass HO; Lavin PT; Moertel CG
Cancer Treat Rep; 1976 Jun; 60(6):769-80. PubMed ID: 782699
[TBL] [Abstract][Full Text] [Related]
11. Case report: acute leukemia after semustine (methyl-CCNU) therapy.
Uphouse WJ; Oishi N
Cancer Treat Rep; 1982 Jul; 66(7):1593-4. PubMed ID: 6953997
[No Abstract] [Full Text] [Related]
12. A controlled study of 5-fluorouracil versus 5-fluorouracil and methyl-CCNU in advanced gastrointestinal adenocarcinoma.
Abdallah AM; Soukop M; Bell G; Calman KC
Clin Oncol; 1977 Sep; 3(3):247-57. PubMed ID: 334430
[No Abstract] [Full Text] [Related]
13. Carcinogenicity of nitrosoureas in humans.
Preussmann R
IARC Sci Publ; 1986; (78):223-9. PubMed ID: 3583392
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of advanced digestive cancer with fluorouracil and methyl-CCNU].
Fleischer I; Wainstein R; Jovtis S; Colombato LO
Acta Gastroenterol Latinoam; 1978; 8(3):191-3. PubMed ID: 747086
[TBL] [Abstract][Full Text] [Related]
15. Acute leukemia after alkylating-agent therapy of ovarian cancer.
Reimer RR; Hoover R; Fraumeni JF; Young RC
N Engl J Med; 1977 Jul; 297(4):177-81. PubMed ID: 406560
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma.
Tornyos K; Silberman H; Solomon A
Cancer Treat Rep; 1977 Aug; 61(5):785-7. PubMed ID: 329977
[TBL] [Abstract][Full Text] [Related]
17. Leukemia after cytotoxic chemotherapy--a pyrrhic victory?
Calabresi P
N Engl J Med; 1983 Nov; 309(18):1118-9. PubMed ID: 6621652
[No Abstract] [Full Text] [Related]
18. Nitrosoureas: a review of experimental antitumor activity.
Schabel FM
Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
[TBL] [Abstract][Full Text] [Related]
19. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.
Socié G; Henry-Amar M; Bacigalupo A; Hows J; Tichelli A; Ljungman P; McCann SR; Frickhofen N; Van't Veer-Korthof E; Gluckman E
N Engl J Med; 1993 Oct; 329(16):1152-7. PubMed ID: 8377778
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
White LA; Perry MC; Kardinal CG; Kennedy BJ; Weiss RB; Carey RW
Cancer Treat Rep; 1979 Feb; 63(2):215-7. PubMed ID: 445497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
